Company Focus
Moderna
Latest Moderna News
Biotechnology
US mRNA specialist Moderna has announced that the UK Court of Appeal has upheld the validity of its EP'949 patent. 1 August 2025
Related News
Insights
Company Spotlight
A Swiss biotech company focussed on antibody discovery and development.
Latest News & Features of interest to Moderna
Pharmaceutical
Last week, PureTech Health spun out a new company, Celea Therapeutics, which will develop its pulmonary fibrosis candidate deupirfenidone (LYT-100). The US Food and Drug Administration (FDA) granted approval for Insmed’s Brinsupri (brensocatib) for the treatment of a chronic inflammatory lung condition. Last week also saw US biotech Sarepta Therapeutics selling 9.3 million shares in Arrowhead, raising around $174 million, and transferring around $50 million to Arrowhead. Basilea in-licensed rights to Venatorx’ urinary tract infection candidate ceftibuten-ledaborbactam etzadroxil. 17 August 2025
Pharmaceutical
The Swiss government has met with senior executives from Roche and Novartis to discuss the outlook for the pharmaceutical industry amid escalating US trade measures. 15 August 2025
Pharmaceutical
The US Department of Health and Human Services has reinstated the Task Force on Safer Childhood Vaccines, a panel created by Congress to strengthen the safety, quality and oversight of vaccines given to American children. The original group was disbanded in 1998. 15 August 2025
Pharmaceutical
Swiss drug developer Basilea Pharmaceutica has entered into an exclusive license agreement with Venatorx Pharmaceuticals, to acquire the global rights to ceftibuten-ledaborbactam etzadroxil. 15 August 2025
Biotechnology
The UK’s National Institute for Health and Care Excellence (NICE) has issued a positive recommendation for AstraZeneca’s Fasenra (benralizumab) for use as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA). 14 August 2025
Biotechnology
China-based RemeGen has announced that its global first-in-class BLyS (BAFF)/APRIL dual-target fusion protein drug, telitacicept, met the primary endpoint in its Phase III clinical trial for the treatment of primary Sjögren's syndrome (pSS) in China, as per the pre-specified study protocol. 14 August 2025
Pharmaceutical
Sarepta Therapeutics, the US biotech, has sold around 9.3 million shares of Arrowhead Pharmaceuticals in a privately negotiated block trade, raising at least $174 million. The move is part of a plan to extend its cash runway while meeting a $100 million milestone owed to Arrowhead. 14 August 2025
Pharmaceutical
Sweden’s Enzymatica has appointed Sana Alajmovic as its new chief executive (CEO), succeeding Claus Egstrand, who has announced that he is stepping down from his operational role, but he will be proposed to join the company’s board of directors in order to ensure continuity. 12 August 2025
Biotechnology
Castleman’s disease (CD) refers to a group of rare lymphoproliferative disorders characterized by abnormal lymph node architecture and systemic inflammation. 12 August 2025
Biotechnology
French manufacturer Sartorius Stedim Biotech and Nanotein Technologies, a developer of next-generation immune cell activation reagents, have entered into a partnership. 11 August 2025
Latest In Brief for Moderna
Biotechnology
Germany’s Boehringer Ingelheim has selected a third drug candidate to move forward into IND-enabling studies under its ongoing collaboration with Oxford BioTherapeutics. 3 July 2025
Latest Relevant Ones To Watch News
Last week, PureTech Health spun out a new company, Celea Therapeutics, which will develop its pulmonary fibrosis candidate deupirfenidone (LYT-100). The US Food and Drug Administration (FDA) granted approval for Insmed’s Brinsupri (brensocatib) for the treatment of a chronic inflammatory lung condition. Last week also saw US biotech Sarepta Therapeutics selling 9.3 million shares in Arrowhead, raising around $174 million, and transferring around $50 million to Arrowhead. Basilea in-licensed rights to Venatorx’ urinary tract infection candidate ceftibuten-ledaborbactam etzadroxil. 17 August 2025
30 June 2025
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze